Presented in part as Abstract 10020 at the 2012 Annual Meeting of the American Society for Clinical Oncology; June 1-5, 2012; Chicago, Illinois.
Sorafenib in patients with progressive epithelioid hemangioendothelioma
A phase 2 study by the French Sarcoma Group (GSF/GETO)
Article first published online: 15 APR 2013
© 2013 American Cancer Society
Volume 119, Issue 14, pages 2639–2644, 15 July 2013
How to Cite
Chevreau, C., Le Cesne, A., Ray-Coquard, I., Italiano, A., Cioffi, A., Isambert, N., Robin, Y. M., Fournier, C., Clisant, S., Chaigneau, L., Bay, J.-O., Bompas, E., Gauthier, E., Blay, J. Y. and Penel, N. (2013), Sorafenib in patients with progressive epithelioid hemangioendothelioma. Cancer, 119: 2639–2644. doi: 10.1002/cncr.28109
We thank all the staff of the Oscar Lambret Center's Clinical Research Unit (Yvette Vendel, Laurence Delannoy, and Emilie Decoupigny) and Severine Marchant for editing the article. We also thank the Institut National du Cancer and Bayer HealthCare for their grants and support.
- Issue published online: 1 JUL 2013
- Article first published online: 15 APR 2013
- Manuscript Accepted: 25 JAN 2013
- Manuscript Revised: 24 JAN 2013
- Manuscript Received: 30 OCT 2012
- phase 2 trial;
- epithelioid hemangioendothelioma;
- orphan diseases;
There is no standard treatment for progressive epithelioid hemangioendothelioma (EHE). To investigate the significant vascularization of EHE, the activity/toxicity of sorafenib in patients with progressive EHE was explored.
In this multicenter, 1-stage, phase 2 trial of sorafenib (800 mg daily), the primary endpoint, which was chosen by default, was the 9-month progression-free rate. All patients had documented progressive disease at the time of study entry.
Fifteen patients were enrolled between June 2009 and February 2011. The median age was 57 years (range, 31-76 years), and the ratio of men to women was 9:6. The performance status was zero in 10 patients and 1 in 5 patients. Twelve patients had metastases, mainly in the lung (12 patients), liver (5 patients), and bone (3 patients). Five patients had received prior chemotherapy (doxorubicin in 5 patients and taxane in 3 patients). The median sorafenib treatment duration was 124 days (range, from 27 to >271 days). Seven patients required dose reductions or transient treatment discontinuation. The 9-month progression-free rate was 30.7% (4 of 13 patients). The 2-month, 4-month, and 6-month progression-free rate was 84.6% (11 of 13 patients), 46.4% (6 of 13 patients), and 38.4% (5 of 13 patients), respectively. Two partial responses were observed that lasted 2 months and 9 months.
Further clinical trials exploring sorafenib as treatment of progressive EHE are needed. Cancer 2013;119:2639–2644. © 2013 American Cancer Society.